Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-C motif chemokine 1 (CCL1), also known as I-309, is a small glycoprotein belonging to the CC chemokine family that is secreted by activated T cells, monocytes, macrophages, and endothelial cells. It acts as a potent chemoattractant primarily for monocytes and T lymphocytes, particularly Th2-differentiated T cells and regulatory T cells (Tregs), by binding to its primary receptor, C-C chemokine receptor type 8 (CCR8). In the tumor microenvironment, the CCL1-CCR8 axis plays a critical role in tumor immune evasion by recruiting immunosuppressive Tregs, which shield tumor cells from cytotoxic T cell attacks. Consequently, targeting CCL1 or its receptor CCR8 has emerged as a highly promising strategy in cancer immunotherapy to deplete tumor-infiltrating Tregs and restore anti-tumor immunity. Beyond oncology, CCL1 is implicated in chronic inflammatory and autoimmune diseases, such as atopic dermatitis, asthma, and rheumatoid arthritis, as well as in pulmonary and hepatic fibrosis through its interaction with CCR8 and the novel receptor autocrine motility factor receptor (AMFR). Therapeutic approaches targeting CCL1 include neutralizing monoclonal antibodies, antisense oligonucleotides, and small-molecule inhibitors designed to disrupt its signaling pathways and restore immune balance.
Neutralization of the chemokine ligand to prevent receptor binding, antisense knockdown of chemokine mRNA to inhibit protein expression, or small-molecule antagonism of its receptor CCR8 to block downstream signaling pathways.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-C motif chemokine 1 (CCL1).